Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

T3011

Phase 2Biologic

IImmVira Pharma Co. Ltd

T3011 is one of 81 biologic programs targeting Advanced Melanoma. It is currently in Phase 2.

3

Indications

8

Total Trials

3

Active Trials

80

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MelanomaRecruiting

Advanced or Metastatic Solid TumorsRecruiting

Urinary Bladder CancerRecruiting

Advanced MelanomaPreclinical

Recruiting

Advanced or Metastatic Solid TumorsPhase 2

Recruiting

Urinary Bladder CancerPhase 2

Recruiting

Competition

Competitive Landscape

62 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Avastin

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vectibix

Adriamycin

Taxane

Bristol-Myers Squibb

Standard Treatment

Boehringer Ingelheim

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Taxotere

Fabhalta

BBellicum Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT04370587

Q2 2029

Phase 2Recruiting

Urinary Bladder Cancer

NCT06971614

Clinical

Trials by Indication[1]

Colorectal Cancer2 trials

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT06200376·10 enrolled

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT06200363·15 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT05602792·233 enrolled

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT05598268·74 enrolled

Advanced Solid Tumors1 trial

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT04780217·42 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting·IImmVira Pharma Co. Ltd·Phase 1/2·NCT04370587·30 enrolled

Urinary Bladder Cancer1 trial

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

Recruiting·IImmVira Pharma Co. Ltd·Phase 2·NCT06971614·160 enrolled

1 more indication

Advanced Melanoma1 trial

A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Preclinical·NCT06214156·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for T3011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — T3011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for T3011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmVira Pharma Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmVira Pharma Co. Ltd

Related News